Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like U*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000090	UCB, Inc	03/31/2022	50474070062	CIMZIA LYOPHOLIZED POWDER FOR INJECTION, 2 X 200 MG VIALS	01/01/2022	284.12	5099.68	02/13/2024	Single Source Drug	1398306000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2022	50474071079	CIMZIA PRE-FILLED SYRINGE KIT, 2 X 200 MG/ML PRE-FILLED SYRINGES	01/01/2022	284.12	5099.68	02/13/2024	Single Source Drug	1398306000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000090	UCB, Inc	03/31/2022	50474071081	CIMZIA PRE-FILLED SYRINGE STARTER KIT, 6 X 200 MG/ML PRE-FILLED SYRINGES	01/01/2022	852.35	15299.03	02/13/2024	Single Source Drug	1398306000	None	None	1	The price increases are not necessitated by a change or improvement in the drugs.	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, the information provided in this report is limited to that which UCB believes is in the public domain or otherwise publicly available. UCB has not provided a response to the drug acquisition related data fields for this drug product because UCB did not acquire this drug product within the previous five years.
Rx0000262	Ultragenyx Pharmaceuticals Inc.	09/30/2022	69794010201	Crysvita 10 mg/mL Subcutaneous Injection 1 Carton	08/01/2022	116.00	3997.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	“Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for the first half of 2022, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.”
Rx0000262	Ultragenyx Pharmaceuticals Inc.	09/30/2022	69794020301	Crysvita 20 mg/mL Subcutaneous Injection 1 Carton	08/01/2022	232.00	7994.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	“Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for the first half of 2022, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.”
Rx0000262	Ultragenyx Pharmaceuticals Inc.	09/30/2022	69794030401	Crysvita 30 mg/mL Subcutaneous Injection 1 Carton	08/01/2022	348.00	11991.00	05/29/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	“Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for the first half of 2022, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.”
Rx0000262	Ultragenyx Pharmaceuticals Inc.	09/30/2022	69794000101	Mepsevii 10 mg/5mL (2mg/mL) Intravenous Injection 1 Carton	08/01/2022	72.00	2486.00	03/05/2035	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	“Ultragenyx is committed to pricing responsibly and have been consistent with any price increases over time based on cost and inflation. After reviewing expenses for the first half of 2022, and recently published market wide inflation data, Ultragenyx has determined the necessity of this pricing action to maintain its operations. We continue to deliver broad access to our therapies, and work to provide patients in the United States who are prescribed an Ultragenyx medicine, with affordable access and patient assistance, up to and including free drug programs to patients who need and qualify. The change in price of the product is not related to changes in the product but is determined after careful consideration of a number of interdependent factors, including but not limited to, clinical and economic value of therapy, therapeutic category, market dynamics, competitor pricing, commercial and government rebates, patient support, overall research and development costs.”
Rx0000036	United Therapeutics	12/31/2022	66302020603	Tyvaso Inhalation Solution 0.6 mg/mL Package of 4 Kits	10/01/2022	132.99	2847.08	12/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036	United Therapeutics	12/31/2022	66302020602	Tyvaso Refill Inhalation Solution 0.6 mg/mL Package of 28 Kits	10/01/2022	930.93	19929.60	12/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036	United Therapeutics	12/31/2022	66302020604	Tyvaso Starter Inhalation Solution 0.6 mg/mL Package of 4 Kits	10/01/2022	240.56	5150.05	12/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036	United Therapeutics	12/31/2022	66302020601	Tyvaso Starter Inhalation Solution 0.6 mg/mL Package of 28 Kits	10/01/2022	1038.50	22232.58	12/15/2028	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	This information is confidential and proprietary, and not publicly available or within the public domain.
Rx0000036	United Therapeutics	03/31/2022	66302001401	Unituxin Dinutuximab; 17.5mg/5mL; Injection/vial; 5mL vial	01/01/2022	1292.64	14349.60	03/01/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Pricing decision was arrived at by taking into account confidential and proprietary information that is not publicly available or within the public domain.